West Michigan Rheumatology has made a two decade committment to advancing the care of patients with rheumatoid arthritis. We and citizens of West Michigan have contributed to the advancement of our knowledge and practice of caring for RA. Together we have participated in a long journey of observational studies of RA as well as investigations evaluating numerous therapeutic targets: Enbrel, Kineret, Remicade, Orencia, Actemra as well as inhibitors of IL-1, CD-4, IL-15, IL-17, gamma interferon, CD20, Blys, and JAK . We have listed only a few of our publications which are linked their abstracts at the National Library of Medicine.
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. N Engl J Med. 2000;343:1586-93.
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Arthritis Rheum. 2002 Jun;46(6):1443-50.
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC. Arthritis Care Res (Hoboken) 2010;63:373-82